Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) U.S. — Reported Sales Growth (%) (%)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, Q4 2025
-19.7%
Period ended Dec 31, 2025
Change on a year earlier
-21.8 pts
2.1% in Q4 2024
History
29 quarters
Since Q4 2018
Sources
29
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) U.S. — Reported Sales Growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q4 2025 | Dec 31, 2025 | -19.7% | -21.8 pts | SEC Filing (0001628280-26-002982) ↗ |
| Q3 2025 | Sep 30, 2025 | -33.5% | -33.3 pts | SEC Filing (0001628280-25-045049) ↗ |
| Q2 2025 | Jun 30, 2025 | -7.1% | +25.0 pts | SEC Filing (0001628280-25-035135) ↗ |
| Q1 2025 | Mar 31, 2025 | -16.9% | +30.0 pts | SEC Filing (0001628280-25-017924) ↗ |
| Q4 2024 | Dec 31, 2024 | 2.1% | +57.4 pts | SEC Filing (0001628280-25-002092) ↗ |
| Q3 2024 | Sep 30, 2024 | -0.2% | +55.7 pts | SEC Filing (0001628280-24-042893) ↗ |
| Q2 2024 | Jun 30, 2024 | -32.1% | +42.3 pts | SEC Filing (0001628280-24-032182) ↗ |
| Q1 2024 | Mar 31, 2024 | -46.9% | +11.5 pts | SEC Filing (0001628280-24-016497) ↗ |
| Q4 2023 | Dec 31, 2023 | -55.3% | -22.3 pts | SEC Filing (0001628280-24-002009) ↗ |
| Q3 2023 | Sep 30, 2023 | -55.9% | -49.3 pts | SEC Filing (0001628280-23-034544) ↗ |
| Q2 2023 | Jun 30, 2023 | -74.4% | -269.8 pts | SEC Filing (0001628280-23-025156) ↗ |
| Q1 2023 | Mar 31, 2023 | -58.4% | -158.8 pts | SEC Filing (0001628280-23-012020) ↗ |
| Q4 2022 | Dec 31, 2022 | -33.0% | -68.3 pts | SEC Filing (0001628280-23-001516) ↗ |
| Q3 2022 | Sep 30, 2022 | -6.6% | -168.0 pts | SEC Filing (0001628280-22-026588) ↗ |
| Q2 2022 | Jun 30, 2022 | 195.4% | +98.2 pts | SEC Filing (0001104659-22-081006) ↗ |
| Q1 2022 | Mar 31, 2022 | 100.4% | -99.3 pts | SEC Filing (0001104659-22-047560) ↗ |
| Q4 2021 | Dec 31, 2021 | 35.3% | -276.9 pts | SEC Filing (0001104659-22-007648) ↗ |
| Q3 2021 | Sep 30, 2021 | 161.4% | +73.1 pts | SEC Filing (0001104659-21-127874) ↗ |
| Q2 2021 | Jun 30, 2021 | 97.2% | +70.3 pts | SEC Filing (0001104659-21-094680) ↗ |
| Q1 2021 | Mar 31, 2021 | 199.7% | +186.7 pts | SEC Filing (0001104659-21-052205) ↗ |
| Q4 2020 | Dec 31, 2020 | 312.2% | +298.6 pts | SEC Filing (0001104659-21-007942) ↗ |
| Q3 2020 | Sep 30, 2020 | 88.3% | +84.7 pts | SEC Filing (0001104659-20-116611) ↗ |
| Q2 2020 | Jun 30, 2020 | 26.9% | +21.5 pts | SEC Filing (0001104659-20-083929) ↗ |
| Q1 2020 | Mar 31, 2020 | 13.0% | +12.4 pts | SEC Filing (0001104659-20-047187) ↗ |
| Q4 2019 | Dec 31, 2019 | 13.6% | +14.5 pts | SEC Filing (0001104659-20-005717) ↗ |
| Q3 2019 | Sep 30, 2019 | 3.6% | – | SEC Filing (0001104659-19-054283) ↗ |
| Q2 2019 | Jun 30, 2019 | 5.4% | – | SEC Filing (0001104659-19-040664) ↗ |
| Q1 2019 | Mar 31, 2019 | 0.6% | – | SEC Filing (0001104659-19-021809) ↗ |
| Q4 2018 | Dec 31, 2018 | -0.9% | – | SEC Filing (0001104659-19-002848) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) U.S. — Reported Sales Growth (%) (%), quarterly Q4 2018–Q4 2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-rapid-leg-yoy-rep-us
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.